An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
NCT03911869
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histologically confirmed diagnosis of cutaneous melanoma with metastases to the brain.
- Presence of B-RAF proto-oncogene, V600 mutant (BRAFV600) mutation in tumor tissue previously determined by a local PCR or NGS-based assay at any time prior to Screening or by a central laboratory during Screening.
- Must have at least 1 parenchymal brain lesion ≥ 0.5 cm and ≤ 4 cm, defined as a magnetic resonance imaging (MRI) contrast-enhancing lesion that may be accurately measured in at least 1 dimension. (Measurable intracranial lesions that have been previously irradiated and have not been shown to be progressing following irradiation should not be considered as target lesions).
- Patients may have received the following prior therapies:
1. Safety Lead-in, Phase 2 Randomized , Phase 2 Arm A Cohort 1: May have received prior local therapy for brain metastases including but not restricted to brain surgery, whole brain radiotherapy, stereotactic radiotherapy or stereotactic radiosurgery. Multiple local (brain) therapies or combinations of local therapies are allowed. For patients receiving local therapy to all brain lesions (including WBRT), progression of pre-existing lesions based on RECIST 1.1 (> 20% increase in longest diameter on baseline scan) or new measurable lesions are required. For patients receiving local therapy for some but not all lesions, disease progression based on RECIST 1.1 is not required as long as there are remaining brain lesions that are measurable and not previously treated.
2. Phase 2 Arm A Cohort 2: Received no prior local therapy (e.g., brain surgery, craniotomy, SRS or SRT) for brain metastases.
3. All patients (Safety Lead-In and Phase 2): May have received prior immunotherapy.
4. All patients (Safety Lead-In and Phase 2): If receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 2 weeks prior to first dose of study treatment (up to a total daily dose of 4mg of dexamethasone or equivalent).
- An Eastern Cooperation Oncology Group Performance Status (ECOG PS) of 0 or 1 and Karnofsky score ≥ 80
- Adequate bone marrow, organ function and laboratory parameters
Key
- Patients with symptomatic brain metastasis.
- Uveal or mucosal melanoma.
- History of or current leptomeningeal metastases.
- Treatment with SRS or craniotomy within 14 days prior to start of study treatment, or
treatment with whole-brain radiation within 28 days prior to study treatment. Patients
who received local therapy should have complete recovery with no neurological
sequelae.
- Either of the following:
1. Radiation therapy to non-brain visceral metastasis within 2 weeks prior to start
of study treatment;
2. Continuous or intermittent small-molecule therapeutics or investigational agents
within 5 half-lives of the agent (or within 4 weeks prior to start of study
treatment, when half-life is unknown).
- Patients treated in the adjuvant setting with BRAF or MEK inhibitor(s) < 6 months
prior to enrollment. Patients who received BRAF or MEK inhibitors in the metastatic
setting are excluded.
- Patient has not recovered to ≤ Grade 1 from toxic effects of prior therapy before
starting study treatment.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Edegem, Antwerpen
- Napoli, Naples
- Encinitas, California
- Los Angeles, California
- Orange, California
- San Francisco, California
- San Francisco, California
- San Francisco, California
- San Francisco, California
- San Francisco, California
- San Marcos, California
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Grand Haven, Michigan
- Grand Haven, Michigan
- Grand Rapids, Michigan
- Grand Rapids, Michigan
- Grand Rapids, Michigan
- Holland, Michigan
- Holland, Michigan
- Muskegon, Michigan
- Muskegon, Michigan
- Norton Shores, Michigan
- Zeeland, Michigan
- Creve Coeur, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Elmwood Park, New Jersey
- Hackensack, New Jersey
- Morristown, New Jersey
- Paramus, New Jersey
- Phillipsburg, New Jersey
- Phillipsburg, New Jersey
- Summit, New Jersey
- West Orange, New Jersey
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Durham, North Carolina
- Durham, North Carolina
- Durham, North Carolina
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Beaverton, Oregon
- Gresham, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Tualatin, Oregon
- Allentown, Pennsylvania
- Bethlehem, Pennsylvania
- Bethlehem, Pennsylvania
- Bethlehem, Pennsylvania
- Coaldale, Pennsylvania
- Easton, Pennsylvania
- Easton, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Quakertown, Pennsylvania
- Stroudsburg, Pennsylvania
- Nashville, Tennessee
- Nashville, Tennessee
- Houston, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Madison, Wisconsin
- Madison, Wisconsin
- Buenos Aires, Ciudad Autónoma DE Buenosaires
- Rosario, Santa FE
- Rosario, Santa FE
- Rosario, Santa FE
- Rosario, Santa FE
- Caba,
- Rosario,
- Coffs Harbour, New South Wales
- Crows Nest, New South Wales
- st Leonards, New South Wales
- Wollstonecraft, New South Wales
- Wollstonecraft, New South Wales
- Adelaide, South Australia
- Adelaide, South Australia
- Bedford park, South Australia
- Seacombe Gardens, South Australia
- Melbourne, Victoria
- Melbourne, Victoria
- Nedlands, Western Australia
- Nedlands,
- Brasschaat, Antwerpen
- Wilrijk, Antwerpen
- Kortrijk,
- Fredericton, New Brunswick
- Milano, Milan
- Milano, MI
- Napoli, Naples
- Padova, Padua
- Meldola (FC), Reggio Emilia
- Padova, Veneto
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milano,
- Milan,
- Napoli,
- Napoli,
- Napoli,
- Napoli,
- Napoli,
- Torino,
- Torino,
- Torino,
- Torino,
- Torino,
- Torino,
- Torino,
- Wellington South, Wellington
- Wellington,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis | ||||||
Official Title ICMJE | A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis | ||||||
Brief Summary | This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain metastasis. Approximately 100 patients will be enrolled, including 9 patients in a Safety Lead-in of the high-dose treatment arm. After a Screening Period, treatment will be administered in 28-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, death. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE | Brain Metastases | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 110 | ||||||
Original Estimated Enrollment ICMJE | 100 | ||||||
Estimated Study Completion Date ICMJE | September 29, 2023 | ||||||
Estimated Primary Completion Date | May 26, 2022 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Key Inclusion Criteria:
Key Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Argentina, Australia, Belgium, Canada, Italy, New Zealand, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03911869 | ||||||
Other Study ID Numbers ICMJE | ARRAY-818-201 C4221006 ( Other Identifier: Alias Study Number ) 2018-004555-21 ( EudraCT Number ) | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |